Reduction in Herpes Zoster Antiviral Use Since the Introduction of the Live-Attenuated Zoster Vaccine on Australia’s National Immunisation Program: A Population-Based Study from 1994 to 2019

Abstract Introduction Zostavax, the live-attenuated vaccine used to prevent herpes zoster (HZ), has been available to individuals aged 70 and 71–79 years (phased catch-up) via Australia’s National Immunisation Program (NIP) since 2016. There are limited data characterising the incidence of HZ at the...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Sachin Phakey, Sophie L. Rogers, Anthony J. Hall, Lyndell L. Lim
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Adis, Springer Healthcare 2023-01-01
Edice:	Infectious Diseases and Therapy
Témata:	Aciclovir Famciclovir Herpes zoster Immunocompromised Immunosuppressed Shingrix
On-line přístup:	https://doi.org/10.1007/s40121-022-00749-y
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!